Eligibility is determined by a licensed clinician after reviewing your intake, history, and current medications, and outcomes vary from person to person
Liu I-M, Tzeng T-F, Liou S-S, Lan T-W
In a recent trial, semaglutide led to a 20% reduction in major adverse cardiovascular events (MACE) in patients with overweight or obesity and established cardiovascular disease, without requiring a diagnosis of diabetes
In SURPASS-2, people with established T2DM treated with tirzepatide 5 to 15 mg for 40 weeks and achieved HbA1c reduction 2.09% to 2.46% compared to 1.86% reduction with semaglutide 1 mg
Factors Affecting the Cost Dosage & Concentration Higher doses cost more
Serum autotaxin is increased in pruritus of cholestasis, but not of other origin, and responds to therapeutic interventions